New approach for assessing glaucoma risk factors is focus of multiyear CME program

    The recommendations of the expert panel will result in the development of innovative content for numerous educational activities, which will help educate ophthalmologists and ophthalmology residents throughout the nation. Additionally, several publications will advance the dissemination of this significant work for the identification and treatment of patients at risk for glaucoma. This educational initiative is supported by two unrestricted educational grants totaling nearly $3.3 million from Pharmacia, now Pfizer Ophthalmics, a division of Pfizer Inc.

    Based on their analysis of long-term, population-based studies of patients with high IOP and glaucoma, the authors of the AJO Perspectives article estimated that treatment may reduce the risk of progressing from untreated high IOP to blindness by a range of 1.2 percent to 8.1 percent over 15 years. They then determined that between 12 and 83 patients with high IOP require treatment to prevent one patient from progressing to unilateral blindness over a 15-year period.

I hope they have some way of measuring the ongoing impact of this CME initiative, because it sounds like it could make a big difference in patient outcomes.

To comment on this post, click on "comments" below. To receive a weekly update, e-mail Sue.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.